Wordt geladen...
Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
The introduction of trastuzumab into clinical practice changed the natural course of HER2-positive breast cancer. Currently, treatment with trastuzumab represents the standard of care for HER2-positive breast cancer and this treatment has been approved in the adjuvant, neoadjuvant, and metastatic se...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4123423/ https://ncbi.nlm.nih.gov/pubmed/23377763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-013-0446-6 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|